ASX: HCT’s Path‐Away® Tests Successful Against SARS-CoV-2

Be the First to Comment Read

ASX: HCT’s Path‐Away® Tests Successful Against SARS-CoV-2

One of the primary US certified environmental testing services, Holista Colltech Limited (ASX:HCT) has completed testing its Path-Away® against the virus SARS-CoV-2 that triggers Covid-19. The research was carried out by Microbac Laboratories, Inc.

Path-Away® attained a 3-Log reduction, about 99.9% of the virus within the span of two minutes, on a hard surface. Log reduction stands for a 10-fold or 90% reduction in numbers of live bacteria. Therefore, a 3-Log reduction suggests 99.9% decline in the likely harmful microorganisms.

Meanwhile, Path-Away® as an anti-pathogenic aerosol solution, was successfully tested on the substitute of SARS-CoV-2 in April 2020.

According to the GICC-LLC, Global Infection Control Consultants, this is expected to be the world’s first completely natural and organic disinfectant, meeting the USA assessment guidelines.

Path-Away® is the active component in sanitizers NatShield™ and Protectene™, both formulated by Holista.

HCT share price quoted at $0.130 at AEDT 01:50 PM on 20 October 2020.

Disclaimer

Speak your Mind

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK